Can I Take St. John's Wort with Finasteride?

How Finasteride Is Metabolized

Finasteride is absorbed rapidly after oral dosing and achieves peak plasma concentration in approximately 2 hours. Its primary metabolic routes involve CYP3A4 alongside minor contributions from other hepatic pathways, and roughly 57% of an oral dose is excreted in urine as metabolites [1]. The plasma half-life averages 5 to 6 hours in younger men and extends to 8 hours in men over 70 [1].

CYP3A4 as the Key Enzyme

CYP3A4 is the most abundant cytochrome P450 enzyme in human liver and intestinal epithelium, responsible for first-pass and systemic metabolism of an estimated 30 to 50% of all marketed drugs [2]. Because finasteride relies partly on this pathway, any agent that induces CYP3A4 activity speeds the breakdown of finasteride and reduces its steady-state concentration.

P-glycoprotein Efflux

Beyond hepatic metabolism, P-glycoprotein (P-gp) expressed in gut enterocytes acts as an efflux pump that can push absorbed finasteride back into the intestinal lumen before it reaches systemic circulation. St. John's Wort induces both CYP3A4 and P-gp through activation of the pregnane X receptor (PXR), meaning the supplement attacks finasteride bioavailability on two fronts simultaneously [3].

What St. John's Wort Does to CYP3A4

St. John's Wort is one of the most extensively documented herbal CYP3A4 inducers in clinical pharmacology. Its active constituents, hyperforin and hypericin, activate PXR, a nuclear receptor that drives transcription of CYP3A4 and MDR1 (the gene encoding P-gp) [3].

Magnitude of CYP3A4 Induction

A crossover pharmacokinetic study published in Clinical Pharmacology and Therapeutics demonstrated that a standardized St. John's Wort extract (300 mg three times daily, 0.3% hypericin) reduced the area under the curve (AUC) of the prototypical CYP3A4 substrate midazolam by approximately 50% after 14 days [4]. That figure is among the largest induction effects observed for any herbal product. A separate analysis in The Lancet found that St. John's Wort reduced cyclosporin plasma concentrations by up to 49%, leading to acute transplant rejection episodes in multiple patients [5].

Induction Onset and Offset

Induction is not immediate. CYP3A4 activity increases progressively over 7 to 14 days of daily St. John's Wort use, peaks at around day 14, and returns toward baseline roughly 14 days after the supplement is discontinued [4]. This time course matters clinically: a person who stops St. John's Wort abruptly while on finasteride may notice the inverse, a temporary rise in finasteride levels as enzyme activity falls back to normal.

Dose Dependence

Hyperforin content drives the induction effect far more than hypericin. Preparations with hyperforin content below 0.1% produce only modest induction in pharmacokinetic studies, whereas standard extracts containing 3 to 5% hyperforin produce the full magnitude seen in clinical trials [3]. Because over-the-counter products vary widely in hyperforin content and labeling is inconsistent, predicting the exact degree of induction from any particular commercial product is difficult.

The Specific Interaction: St. John's Wort and Finasteride

No published randomized trial has measured finasteride plasma concentrations specifically before and after St. John's Wort co-administration. The interaction is inferred from finasteride's established CYP3A4 dependence, the well-characterized magnitude of CYP3A4 induction by St. John's Wort, and the mechanistic principle that inducers reduce substrate AUC proportionally to the degree of enzyme upregulation [2].

Estimated Pharmacokinetic Impact

Finasteride's metabolism is described in its FDA-approved prescribing information as primarily CYP3A4-dependent, though the enzyme's fractional contribution to total clearance (the fm value) is not precisely published in the label [1]. If CYP3A4 accounts for, say, 40 to 60% of finasteride clearance and St. John's Wort reduces CYP3A4 substrate AUC by 30 to 50% in vivo, then a 15 to 30% reduction in finasteride exposure is mechanistically plausible. That range of reduction could be clinically meaningful given that finasteride's dose-response relationship for 5-alpha reductase inhibition is relatively steep at the 1 mg level used for androgenetic alopecia.

Implications for Hair Loss Treatment

The PLESS trial (N=3,040) and supporting pharmacokinetic data established that finasteride 1 mg reduces scalp dihydrotestosterone (DHT) by approximately 64% and serum DHT by roughly 68% at steady state [6]. If St. John's Wort reduces circulating finasteride by even 20%, that DHT suppression may diminish noticeably, and hair preservation or regrowth outcomes could suffer. There are no published cohort data specifically tracking hair density or vertex coverage in men who combine both agents, so the clinical magnitude of outcome change remains an open research question.

Implications for BPH Treatment

For finasteride 5 mg (Proscar) used in benign prostatic hyperplasia, the MTOPS trial (N=3,047) showed that finasteride monotherapy reduced the risk of overall BPH clinical progression by 34% over 4.5 years [7]. A pharmacokinetic interaction that meaningfully reduces finasteride exposure could attenuate the 5-alpha reductase inhibition that drives prostate volume reduction and urinary symptom improvement. Men on finasteride 5 mg for BPH who also use St. John's Wort should monitor symptom scores, such as the International Prostate Symptom Score (IPSS), and report any worsening to their prescriber.

FDA Guidance on St. John's Wort Drug Interactions

The FDA issued a public health advisory specifically warning that St. John's Wort interacts with a large number of prescription drugs by inducing metabolic enzymes [8]. The advisory, first published in 2000, remains current and states that healthcare professionals should alert patients about this interaction profile. The original warning focused on HIV protease inhibitors and cyclosporin, but the FDA's reasoning applies broadly to any CYP3A4-dependent drug, including finasteride [8].

Regulatory Classification of the Interaction

Major drug interaction databases, including those used by hospital pharmacy systems, typically classify the St. John's Wort/CYP3A4 substrate combination as a moderate-to-major interaction depending on the substrate's therapeutic index. Finasteride does not have a narrow therapeutic index in the way warfarin or cyclosporin do, which is why this combination is generally rated moderate rather than contraindicated outright [2]. Moderate, however, does not mean inconsequential, especially for a medication taken long-term for a chronic condition where consistent drug levels matter.

Who Is Most at Risk

Not every person taking both agents will experience the same degree of reduced finasteride exposure. Several factors influence individual risk:

• CYP3A4 genetic variation. People who are already rapid metabolizers at baseline may experience a proportionally larger relative increase in clearance [2].
• St. John's Wort product and dose. Higher hyperforin content and three-times-daily dosing produce greater induction than once-daily low-dose formulations [3].
• Duration of co-administration. Short-term (under 7 days) use produces minimal induction; chronic daily use reaching steady state over 2 to 4 weeks produces maximal enzyme upregulation [4].
• Finasteride dose. Men on the 1 mg dose for alopecia likely have less pharmacokinetic buffer than those on 5 mg for BPH, because there is less absolute drug to spare.

Monitoring and What to Do

If You Are Already Taking Both

Do not stop either agent abruptly without speaking to your prescriber. Stopping St. John's Wort suddenly may cause a transient overshoot in finasteride levels as CYP3A4 activity normalizes over roughly 14 days [4]. While that overshoot is unlikely to cause serious harm at finasteride doses of 1 to 5 mg, it is another reason to taper or time any changes under medical supervision.

Laboratory and Clinical Monitoring

Serum DHT measurement is not routinely ordered in clinical practice for finasteride users, but it is available and could, in principle, confirm whether DHT suppression remains adequate. For BPH patients, tracking IPSS, peak urinary flow rate (Qmax), and prostate-specific antigen (PSA) every 6 to 12 months is already standard of care per American Urological Association guidelines [9]. Any unexpected loss of symptom control or PSA rise in a man co-using St. John's Wort warrants investigation.

Discussing Alternatives

St. John's Wort is used most commonly for mild to moderate depression. Evidence from a Cochrane systematic review of 29 trials (N=5,489) found that Hypericum extracts were superior to placebo (risk ratio 1.48; 95% CI 1.23 to 1.77) and similarly effective to standard antidepressants for mild to moderate depression, with fewer side effects [10]. However, given the drug interaction profile, a prescriber may reasonably recommend switching to a first-line antidepressant with lower CYP3A4 interaction risk, such as sertraline, if maintaining adequate finasteride exposure is a treatment priority.

Pharmacodynamic Considerations

The interaction between St. John's Wort and finasteride is primarily pharmacokinetic, not pharmacodynamic. There is no known direct biochemical antagonism between hypericin or hyperforin and 5-alpha reductase type II, the enzyme finasteride inhibits. St. John's Wort does not raise androgens or DHT on its own to a clinically meaningful degree in published human studies, so the concern is exclusively about reduced finasteride blood levels rather than any opposing hormonal effect [3].

Mood and Hair Loss

One point worth acknowledging: finasteride itself carries an FDA label warning regarding post-finasteride syndrome and rare reports of persistent sexual and mood-related side effects [1]. Some patients taking finasteride may reach for St. John's Wort to manage mood changes they attribute to the drug. If that is the situation, disclosing both to a prescriber is important, because the interaction adds complexity to the clinical picture and because mood symptoms during finasteride therapy merit direct evaluation rather than self-treatment.

Practical Guidance for Patients and Clinicians

The safest approach is to avoid concurrent use of high-hyperforin St. John's Wort preparations and finasteride unless a prescriber has reviewed the combination and judged that the therapeutic tradeoff is acceptable. If a patient declines to discontinue St. John's Wort, the prescriber may consider monitoring clinical endpoints more frequently: for alopecia, standardized photography every 3 to 6 months; for BPH, IPSS scoring at each visit.

Patients should also be reminded that "natural" does not mean non-interacting. The FDA advisory from 2000 makes this explicit, noting that herbal products can cause "serious pharmacokinetic interactions" with prescription medications through the same enzyme pathways as synthetic inducers [8]. Disclosing all supplements at each clinic visit is the single most reliable way to catch interactions before they affect outcomes.

The American Academy of Family Physicians recommends that clinicians ask patients specifically about herbal and dietary supplement use at every medication review, since patients frequently do not volunteer this information voluntarily [11]. Structured medication reconciliation checklists that include supplements, not just prescription drugs, close this documentation gap.